leflunomide has been researched along with Chronic Kidney Failure in 6 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease." | 7.79 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ( Bergner, R; Löffler, C; Peters, L; Schmitt, V, 2013) |
| " We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease." | 3.79 | Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ( Bergner, R; Löffler, C; Peters, L; Schmitt, V, 2013) |
| "In patients with IgA nephropathy and proteinuria > 1 g/day, steroid therapy given for generally two to four months with a tapering course probably prevents the progression to ESKD compared to placebo or standard care (8 studies; 741 participants: RR 0." | 2.66 | Immunosuppressive agents for treating IgA nephropathy. ( Craig, JC; Molony, DA; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Samuels, JA; Schena, FP; Strippoli, GF; Vecchio, M, 2020) |
| " The dosage was increased to 20 mg/day after 3 months." | 1.39 | Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. ( Ahern, MJ; Barbara, JA; Russo, PA; Shanahan, EM; Smith, MD; Wiese, MD, 2013) |
| "Prior to admission, she had been treated for rheumatoid arthritis with methotrexate 7." | 1.31 | Effect of hemodialysis on leflunomide plasma concentrations. ( Beaman, JM; Hackett, LP; Illett, KF; Luxton, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Natale, P | 1 |
| Palmer, SC | 1 |
| Ruospo, M | 1 |
| Saglimbene, VM | 1 |
| Craig, JC | 1 |
| Vecchio, M | 1 |
| Samuels, JA | 1 |
| Molony, DA | 1 |
| Schena, FP | 1 |
| Strippoli, GF | 1 |
| Russo, PA | 1 |
| Wiese, MD | 1 |
| Smith, MD | 1 |
| Ahern, MJ | 1 |
| Barbara, JA | 1 |
| Shanahan, EM | 1 |
| Yang, D | 1 |
| Keys, B | 1 |
| J Conti, D | 1 |
| Foulke, L | 1 |
| Stellrecht, K | 1 |
| Cook, L | 1 |
| Lopez-Soler, RI | 1 |
| Araya, CE | 1 |
| Garin, EH | 1 |
| Neiberger, RE | 1 |
| Dharnidharka, VR | 1 |
| Bergner, R | 1 |
| Peters, L | 1 |
| Schmitt, V | 1 |
| Löffler, C | 1 |
| Beaman, JM | 1 |
| Hackett, LP | 1 |
| Luxton, G | 1 |
| Illett, KF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study[NCT02758288] | 0 participants (Actual) | Observational | 2015-09-30 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for leflunomide and Chronic Kidney Failure
| Article | Year |
|---|---|
Immunosuppressive agents for treating IgA nephropathy.
Topics: Adult; Calcineurin Inhibitors; Cause of Death; Child; Confidence Intervals; Creatinine; Drug Adminis | 2020 |
JC polyomavirus nephropathy, a rare cause of transplant dysfunction: Case report and review of literature.
Topics: Biopsy; BK Virus; Creatinine; Graft Rejection; Humans; Immunoglobulins, Intravenous; Immunosuppressi | 2017 |
4 other studies available for leflunomide and Chronic Kidney Failure
| Article | Year |
|---|---|
Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Psoriatic; Aryl Hydr | 2013 |
Leflunomide therapy for BK virus allograft nephropathy in pediatric and young adult kidney transplant recipients.
Topics: Antiviral Agents; BK Virus; Child; DNA, Viral; Dose-Response Relationship, Drug; Enzyme Inhibitors; | 2010 |
Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Crotonates; Female; Hum | 2013 |
Effect of hemodialysis on leflunomide plasma concentrations.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Biotrans | 2002 |